These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 18517170)

  • 1. Patient safety challenges in treprostinil therapy.
    Roncesvalles A; Lee FW; Camamo J; Priestley G
    Medsurg Nurs; 2008 Apr; 17(2):101-6. PubMed ID: 18517170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical aspects of continuous intravenous treprostinil therapy.
    Widlitz AC; McDevitt S; Ward GR; Krichman A
    Crit Care Nurse; 2007 Apr; 27(2):41-2, 44-5, 47-50; quiz 51. PubMed ID: 17389412
    [No Abstract]   [Full Text] [Related]  

  • 3. Treprostinil for pulmonary hypertension.
    Vachiéry JL; Naeije R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Education of patients treated with a continuous epoprostenol infusion for pulmonary hypertension].
    Marlier D
    Soins; 2006 May; (705 Suppl):S7-12. PubMed ID: 16771257
    [No Abstract]   [Full Text] [Related]  

  • 5. Advances in prostacyclin therapy for pulmonary arterial hypertension.
    Eells PL
    Crit Care Nurse; 2004 Apr; 24(2):42-8, 50-4. PubMed ID: 15098310
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostacycline (Flolan). Intravenous nursing responsibilities in the care of the patient with primary pulmonary hypertension.
    Benvenuto DB
    J Intraven Nurs; 1999; 22(5):267-72. PubMed ID: 10776190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
    Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H
    Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous epoprostenol: a new therapy for primary pulmonary hypertension.
    Sabo JA; Nord CP
    Crit Care Nurse; 2000 Dec; 20(6):31-40. PubMed ID: 11878257
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances in prostanoid infusion therapy for pulmonary arterial hypertension.
    Doran A; Harris S; Goetz B
    J Infus Nurs; 2008; 31(6):336-45. PubMed ID: 19018187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
    Mathier MA; McDevitt S; Saggar R
    J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous improvement process for a high-risk population: catheter-directed thrombolytic infusions.
    Morris J; Neaton M
    J Vasc Nurs; 2009 Mar; 27(1):8-12. PubMed ID: 19217539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
    Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
    J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treprostinil: new drug. Pulmonary artery hypertension: just another (disappointing) prostacycline analogue.
    Prescrire Int; 2006 Oct; 15(85):177-9. PubMed ID: 17128524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deploying med reconciliation.
    Williams T; Acton C; Hicks RW
    Nurs Manage; 2008 Apr; 39(4):54-7. PubMed ID: 18391828
    [No Abstract]   [Full Text] [Related]  

  • 16. Treprostinil for the treatment of pulmonary arterial hypertension in patients with New York Heart Association class II-IV symptoms.
    Herald N; Laliberte K
    Pharmacotherapy; 2006 Aug; 26(8):1203; discussion 1203-4. PubMed ID: 16863500
    [No Abstract]   [Full Text] [Related]  

  • 17. Moderate-term effect of epoprostenol on severe portopulmonary hypertension.
    Kato H; Katori T; Nakamura Y; Kawarasaki H
    Pediatr Cardiol; 2003; 24(1):50-3. PubMed ID: 12574979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treprostinil (Remodulin) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2002 Sep; 44(1139):80-2. PubMed ID: 12237619
    [No Abstract]   [Full Text] [Related]  

  • 19. Continuous intravenous prostacyclin for advanced primary pulmonary hypertension.
    Archer-Chicko C
    Dimens Crit Care Nurs; 2000; 19(2):14-21. PubMed ID: 10876492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension.
    Tapson VF; McLaughlin VV; Gomberg-Maitland M; Widlitz AC; Krichman AD; Laliberte KJ; Zaccardelli DS; Barst RJ
    J Vasc Access; 2006; 7(3):112-7. PubMed ID: 17019662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.